Monitoring Immune Responses in Neuroblastoma Patients during Therapy

Monitoring Immune Responses in Neuroblastoma Patients during Therapy

Neuroblastoma (NBL) is the most common extracranial solid tumor in childhood. Despite intense treatment, children with this high-risk disease have a poor prognosis. Immunotherapy showed a significant improvement in event-free survival in high-risk NBL patients receiving chimeric anti-GD2 in combinat...

Full description

Bibliographic Details
Main Authors:	Celina L. Szanto, Annelisa M. Cornel, Saskia V. Vijver, Stefan Nierkens
Format:	Article
Language:	English
Published:	MDPI AG 2020-02-01
Series:	Cancers
Subjects:	neuroblastoma biomarker immunotherapy anti-gd2 dinutuximab immune profiling immune monitoring adoptive cell therapy checkpoint inhibitors cytokines
Online Access:	https://www.mdpi.com/2072-6694/12/2/519

Similar Items

Treatment-Related Toxicities During Anti-GD2 Immunotherapy in High-Risk Neuroblastoma Patients
by: Thomas Blom, et al.
Published: (2021-02-01)

Clinical Phenotype and Management of Severe Neurotoxicity Observed in Patients with Neuroblastoma Treated with Dinutuximab Beta in Clinical Trials
by: Fiedler, S., et al.
Published: (2022)

Investigation of the Role of Dinutuximab Beta-Based Immunotherapy in the SIOPEN High-Risk Neuroblastoma 1 Trial (HR-NBL1)
by: Ruth Ladenstein, et al.
Published: (2020-01-01)

Ex vivo expanded patient-derived γδ T-cell immunotherapy enhances neuroblastoma tumor regression in a murine model
by: Jaquelyn T. Zoine, et al.
Published: (2019-08-01)

Immune Monitoring during Therapy Reveals Activitory and Regulatory Immune Responses in High-Risk Neuroblastoma
by: Celina L. Szanto, et al.
Published: (2021-04-01)

Impact of IL-2 on Treatment Tolerance in Patients With High-Risk Neuroblastoma Treated With Dinutuximab Beta-Based Immunotherapy
by: Filiz Cicek, et al.
Published: (2020-12-01)

Novel drug - dinutuximab for high-risk neuroblastoma
by: Supriya Kushwah, et al.
Published: (2018-01-01)

Efficacy and safety of regorafenib versus dinutuximab with chemotherapy in Chinese children with neuroblastoma
by: Kun Dong, et al.
Published: (2019-02-01)

Efficacy and safety of regorafenib versus dinutuximab with chemotherapy in Chinese children with neuroblastoma
by: Kun Dong, et al.
Published: (2019-02-01)

Local delivery of dinutuximab from lyophilized silk fibroin foams for treatment of an orthotopic neuroblastoma model
by: Kimberly J. Ornell, et al.
Published: (2020-04-01)

CD47-SIRPα Checkpoint Inhibition Enhances Neutrophil-Mediated Killing of Dinutuximab-Opsonized Neuroblastoma Cells
by: Paula Martínez-Sanz, et al.
Published: (2021-08-01)

A Comprehensive Safety Trial of Chimeric Antibody 14.18 With GM-CSF, IL-2, and Isotretinoin in High-Risk Neuroblastoma Patients Following Myeloablative Therapy: Children’s Oncology Group Study ANBL0931
by: M. Fevzi Ozkaynak, et al.
Published: (2018-06-01)

Corrigendum: A Comprehensive Safety Trial of Chimeric Antibody 14.18 With GM-CSF, IL-2, and Isotretinoin in High-Risk Neuroblastoma Patients Following Myeloablative Therapy: Children’s Oncology Group Study ANBL0931
by: M. Fevzi Ozkaynak, et al.
Published: (2018-07-01)

Immune landscape of inflammatory breast cancer suggests vulnerability to immune checkpoint inhibitors
by: François Bertucci, et al.
Published: (2021-01-01)

Predictive biomarkers for tumor immune checkpoint blockade
by: Tong M, et al.
Published: (2018-10-01)

Combinatorial Approaches With Checkpoint Inhibitors to Enhance Anti-tumor Immunity
by: Barbara Seliger
Published: (2019-05-01)

Spotlight on dinutuximab in the treatment of high-risk neuroblastoma: development and place in therapy
by: Keyel ME, et al.
Published: (2018-12-01)

Biological Factors behind Melanoma Response to Immune Checkpoint Inhibitors
by: Magdalena Olbryt, et al.
Published: (2020-06-01)

Talkin’ Toxins: From Coley’s to Modern Cancer Immunotherapy
by: Robert D. Carlson, et al.
Published: (2020-04-01)

Intratumoral immunosuppression profiles in 11q‐deleted neuroblastomas provide new potential therapeutic targets
by: Esther Coronado, et al.
Published: (2021-02-01)

Anxiolytic and hypnotic effects of Cocculus laurifolius leaf extract in mice
by: Sidra Maqbool, et al.
Published: (2019-02-01)

Immune landscape and in vivo immunogenicity of NY-ESO-1 tumor antigen in advanced neuroblastoma patients
by: Chiara Camisaschi, et al.
Published: (2018-10-01)

The Tumor and Host Immune Signature, and the Gut Microbiota as Predictive Biomarkers for Immune Checkpoint Inhibitor Response in Melanoma Patients
by: Katarzyna Tomela, et al.
Published: (2020-09-01)

Distinct signatures of the immune responses in low risk versus high risk neuroblastoma
by: Wang Ena, et al.
Published: (2011-10-01)

Exploration of Feasible Immune Biomarkers for Immune Checkpoint Inhibitors in Head and Neck Squamous Cell Carcinoma Treatment in Real World Clinical Practice
by: Hui-Ching Wang, et al.
Published: (2020-10-01)

Identifying baseline immune-related biomarkers to predict clinical outcome of immunotherapy
by: Sacha Gnjatic, et al.
Published: (2017-05-01)

Peripheral Blood-Based Biomarkers for Immune Checkpoint Inhibitors
by: Ho Jung An, et al.
Published: (2021-08-01)

Real world clinicopathologic observations of patients with metastatic solid tumors receiving immune checkpoint inhibitor therapy: Analysis from Kentucky Cancer Registry
by: Aasems Jacob, et al.
Published: (2021-03-01)

The ascent of immune checkpoint inhibitors: is the understudy ready for a leading role?
by: Amy L. Cummings, et al.
Published: (2017-08-01)

Anti-GD2 antibody and Vorinostat immunocombination therapy is highly effective in an aggressive orthotopic neuroblastoma model
by: Renske J. E. van den Bijgaart, et al.
Published: (2020-01-01)

Lymph Node Immune Profiles as Predictive Biomarkers for Immune Checkpoint Inhibitor Response
by: Emily F. Goode, et al.
Published: (2021-05-01)

Challenges to Successful Implementation of the Immune Checkpoint Inhibitors for Treatment of Glioblastoma
by: Stephanie Sanders, et al.
Published: (2020-04-01)

Hyperprogressive Disease in Cancers Treated With Immune Checkpoint Inhibitors
by: Pan Shen, et al.
Published: (2021-07-01)

Evidence for the efficacy of immunotherapy in children with high-risk neuroblastoma
by: Elwira Szychot, et al.
Published: (2016-09-01)

VISTA: A Promising Target for Cancer Immunotherapy?
by: Tagliamento M, et al.
Published: (2021-06-01)

Immune Therapy Resistance and Immune Escape of Tumors
by: Barbara Seliger, et al.
Published: (2021-02-01)

Immune oncology, immune responsiveness and the theory of everything
by: Tolga Turan, et al.
Published: (2018-06-01)

Tumor matrix remodeling and novel immunotherapies: the promise of matrix-derived immune biomarkers
by: Muhammad Umair Mushtaq, et al.
Published: (2018-07-01)

Combined immune checkpoint blockade increases CD8+CD28+PD-1+ effector T cells and provides a therapeutic strategy for patients with neuroblastoma
by: Soheila Shirinbak, et al.
Published: (2021-01-01)

Clinical diagnosis and treatment of immune checkpoint inhibitor‐associated pneumonitis
by: Hanping Wang, et al.
Published: (2020-01-01)